TapewireFind a company

person · Reporting owner

SACHS BRUCE I

Disclosed activity across 1 company

Tapewire entity
14205
SEC CIK
0001197036

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875DirectorAugust 27, 2026August 31, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

VERTEX PHARMACEUTICALS INC / MA

Report date August 27, 2026 · Filed August 31, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect39,000 Reported balance After 2026-08-27 transaction · row 1
1 source row

Row 1 · 2026-08-27 · Gift · Disposed 6,000 · Balance 39,000

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 01, 2018 Filed Jun 5, 2018 21:32 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 2,188 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-035849 · doc4.xml · derivative · entry 4

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,587.164

Underlying: Common Stock · 2,188 shares

Expires not disclosed

F4 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F2 · price: Upon the vesting of restricted stock units granted to Mr. Sachs on June 1, 2017, Mr. Sachs deferred the receipt of 2,188 shares of common stock and received instead 2,188 deferred stock units pursuant to the Company's deferred compensation plan. As a result, Mr. Sachs is reporting the disposition of 2,188 shares of common stock in exchange for an equal number of deferred stock units.

F4 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F4 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
June 01, 2018 Filed Jun 5, 2018 21:32 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantStock Option (Right to Buy) · Derivative 3,229 $0.00 Strike: $152.74 $0.00
Disclosure

SEC source: 0001209191-18-035849 · doc4.xml · derivative · entry 3

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,229

Underlying: Common Stock · 3,229 shares

Expires 2028-05-31

F3 · derivative.exercise_date: Fully vested.

Read SEC document
June 01, 2018 Filed Jun 5, 2018 21:32 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Disposition to issuerCommon Stock 2,188 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-035849 · doc4.xml · nonDerivative · entry 2

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,011

F2 · price: Upon the vesting of restricted stock units granted to Mr. Sachs on June 1, 2017, Mr. Sachs deferred the receipt of 2,188 shares of common stock and received instead 2,188 deferred stock units pursuant to the Company's deferred compensation plan. As a result, Mr. Sachs is reporting the disposition of 2,188 shares of common stock in exchange for an equal number of deferred stock units.

Read SEC document
June 01, 2018 Filed Jun 5, 2018 21:32 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantCommon Stock 1,801 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-035849 · doc4.xml · nonDerivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,199

F1 · shares: Restricted stock unit that vests, subject to certain limited exceptions, on the first anniversary of the grant date.

Read SEC document
April 16, 2018 Filed Apr 18, 2018 18:51 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 279.695 $160.89 $45,000.13
Disclosure

SEC source: 0001209191-18-025337 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,399.164

Underlying: Common Stock · 279.695 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
January 16, 2018 Filed Jan 17, 2018 21:43 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 261.905 $157.50 $41,250.04
Disclosure

SEC source: 0001209191-18-003974 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,119.469

Underlying: Common Stock · 261.905 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) the termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) the termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) the termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
December 20, 2017 Filed Jan 17, 2018 21:42 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GiftCommon Stock 10,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-003972 · doc5.xml · nonDerivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,398

F1 · kind: Represents a gift to a charitable foundation.

Read SEC document
October 16, 2017 Filed Oct 18, 2017 21:31 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 265.376 $155.44 $41,250.05
Disclosure

SEC source: 0001209191-17-057316 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,857.564

Underlying: Common Stock · 265.376 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) the termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) the termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) the termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
July 17, 2017 Filed Jul 19, 2017 21:02 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 316.942 $130.15 $41,250.00
Disclosure

SEC source: 0001209191-17-045725 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,592.188

Underlying: Common Stock · 316.942 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
June 01, 2017 Filed Jun 5, 2017 22:00 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 2,941 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-17-037913 · doc4.xml · derivative · entry 4

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,275.246

Underlying: Common Stock · 2,941 shares

Expires not disclosed

F4 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F2 · price: Upon the vesting of restricted stock units granted to Mr. Sachs on June 1, 2016, Mr. Sachs deferred the receipt of 2,941 shares of common stock and received instead 2,941 deferred stock units pursuant to the Company's deferred compensation plan. As a result, Mr. Sachs is reporting the disposition of 2,941 shares of common stock in exchange for an equal number of deferred stock units.

F4 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F4 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
June 01, 2017 Filed Jun 5, 2017 22:00 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantStock Option (Right to Buy) · Derivative 5,295 $0.00 Strike: $125.71 $0.00
Disclosure

SEC source: 0001209191-17-037913 · doc4.xml · derivative · entry 3

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,295

Underlying: Common Stock · 5,295 shares

Expires 2027-05-31

F3 · derivative.exercise_date: Fully vested.

Read SEC document
June 01, 2017 Filed Jun 5, 2017 22:00 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Disposition to issuerCommon Stock 2,941 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-17-037913 · doc4.xml · nonDerivative · entry 2

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,398

F2 · price: Upon the vesting of restricted stock units granted to Mr. Sachs on June 1, 2016, Mr. Sachs deferred the receipt of 2,941 shares of common stock and received instead 2,941 deferred stock units pursuant to the Company's deferred compensation plan. As a result, Mr. Sachs is reporting the disposition of 2,941 shares of common stock in exchange for an equal number of deferred stock units.

Read SEC document
June 01, 2017 Filed Jun 5, 2017 22:00 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantCommon Stock 2,188 $0.00 $0.00
Disclosure

SEC source: 0001209191-17-037913 · doc4.xml · nonDerivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,339

F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.

Read SEC document
April 17, 2017 Filed Apr 19, 2017 21:10 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 360.011 $114.58 $41,250.06
Disclosure

SEC source: 0001209191-17-027500 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,334.246

Underlying: Common Stock · 360.011 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
January 17, 2017 Filed Jan 19, 2017 17:33 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 508.256 $81.16 $41,250.06
Disclosure

SEC source: 0001209191-17-004375 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,974.235

Underlying: Common Stock · 508.256 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
October 17, 2016 Filed Oct 19, 2016 18:33 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 515.561 $80.01 $41,250.04
Disclosure

SEC source: 0001209191-16-146305 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,465.979

Underlying: Common Stock · 515.561 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
July 15, 2016 Filed Jul 19, 2016 20:46 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 461.152 $89.45 $41,250.05
Disclosure

SEC source: 0001209191-16-133321 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 950.418

Underlying: Common Stock · 461.152 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
June 01, 2016 Filed Jun 3, 2016 21:09 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantStock Option (Right to Buy) · Derivative 7,073 $0.00 Strike: $93.51 $0.00
Disclosure

SEC source: 0001209191-16-125721 · doc4.xml · derivative · entry 2

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,073

Underlying: Common Stock · 7,073 shares

Expires 2026-05-31

F2 · derivative.exercise_date: Fully vested.

Read SEC document
June 01, 2016 Filed Jun 3, 2016 21:09 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantCommon Stock 2,941 $0.01 $29.41
Disclosure

SEC source: 0001209191-16-125721 · doc4.xml · nonDerivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,151

F1 · shares: Restricted stock unit award that vests on the first anniversary of the grant date.

Read SEC document
April 15, 2016 Filed Apr 19, 2016 22:17 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 489.266 $87.60 $42,859.70
Disclosure

SEC source: 0001209191-16-114922 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 489.266

Underlying: Common Stock · 489.266 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
August 04, 2015 Filed Aug 5, 2015 20:18 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $34.24 $0.00
Disclosure

SEC source: 0001209191-15-064032 · doc4.xml · derivative · entry 3

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2020-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully vested.

Read SEC document
August 04, 2015 Filed Aug 5, 2015 20:18 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 10,000 $140.13 $1,401,300.00
Disclosure

SEC source: 0001209191-15-064032 · doc4.xml · nonDerivative · entry 2

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,210

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1.

F2 · price: Open market sales reported on this line occurred at a weighted average price of $140.13 (range $140.00 to $140.45).

F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Read SEC document
August 04, 2015 Filed Aug 5, 2015 20:18 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionCommon Stock 10,000 $34.24 $342,400.00
Disclosure

SEC source: 0001209191-15-064032 · doc4.xml · nonDerivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,210

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 01, 2015 Filed Jun 3, 2015 20:45 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantStock Option · Derivative 22,500 $0.00 Strike: $127.54 $0.00
Disclosure

SEC source: 0001209191-15-049644 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2025-05-31

F1 · derivative.exercise_date: Fully vested.

Read SEC document
March 20, 2015 Filed Mar 24, 2015 22:04 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $29.89 $0.00
Disclosure

SEC source: 0001209191-15-028974 · doc4.xml · derivative · entry 4

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2019-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Fully vested.

Read SEC document
March 20, 2015 Filed Mar 24, 2015 22:04 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 1,375 $136.14 $187,192.50
Disclosure

SEC source: 0001209191-15-028974 · doc4.xml · nonDerivative · entry 3

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,210

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1.

F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4 · price: Open market sales reported on this line occurred at a weighted average price of $136.14 (range $136.00 to $136.33).

Read SEC document
March 20, 2015 Filed Mar 24, 2015 22:04 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 8,625 $135.42 $1,167,997.50
Disclosure

SEC source: 0001209191-15-028974 · doc4.xml · nonDerivative · entry 2

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,585

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1.

F2 · price: Open market sales reported on this line occurred at a weighted average price of $135.42 (range $135.00 to $135.99).

F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Read SEC document
March 20, 2015 Filed Mar 24, 2015 22:04 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionCommon Stock 10,000 $29.89 $298,900.00
Disclosure

SEC source: 0001209191-15-028974 · doc4.xml · nonDerivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,210

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 18, 2015 Filed Mar 20, 2015 20:19 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $29.89 $0.00
Disclosure

SEC source: 0001209191-15-028202 · doc4.xml · derivative · entry 3

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2019-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully vested.

Read SEC document
March 18, 2015 Filed Mar 20, 2015 20:19 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 10,000 $130.13 $1,301,300.00
Disclosure

SEC source: 0001209191-15-028202 · doc4.xml · nonDerivative · entry 2

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,210

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1.

F2 · price: Open market sales reported on this line occurred at a weighted average price of $130.13 (range $130.00 to $130.52).

F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Read SEC document
March 18, 2015 Filed Mar 20, 2015 20:19 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionCommon Stock 10,000 $29.89 $298,900.00
Disclosure

SEC source: 0001209191-15-028202 · doc4.xml · nonDerivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,210

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 20, 2015 Filed Jan 22, 2015 22:24 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionStock Option (right to buy) · Derivative 139 $0.00 Strike: $28.40 $0.00
Disclosure

SEC source: 0001209191-15-005886 · doc4.xml · derivative · entry 3

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 139 shares

Expires 2018-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested.

Read SEC document
January 20, 2015 Filed Jan 22, 2015 22:24 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 139 $125.00 $17,375.00
Disclosure

SEC source: 0001209191-15-005886 · doc4.xml · nonDerivative · entry 2

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,210

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1.

Read SEC document
January 20, 2015 Filed Jan 22, 2015 22:24 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionCommon Stock 139 $28.40 $3,947.60
Disclosure

SEC source: 0001209191-15-005886 · doc4.xml · nonDerivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,349

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 09, 2015 Filed Jan 13, 2015 21:17 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionStock Option (right to buy) · Derivative 9,861 $0.00 Strike: $28.40 $0.00
Disclosure

SEC source: 0001209191-15-003887 · doc4.xml · derivative · entry 3

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139

Underlying: Common Stock · 9,861 shares

Expires 2018-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully vested.

Read SEC document
January 09, 2015 Filed Jan 13, 2015 21:17 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 9,861 $125.04 $1,233,019.44
Disclosure

SEC source: 0001209191-15-003887 · doc4.xml · nonDerivative · entry 2

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,210

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1.

F2 · price: Open market sales reported on this line occurred at a weighted average price of $125.04 (range $125.00 to $125.25).

F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Read SEC document
January 09, 2015 Filed Jan 13, 2015 21:17 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionCommon Stock 9,861 $28.40 $280,052.40
Disclosure

SEC source: 0001209191-15-003887 · doc4.xml · nonDerivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,071

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 28, 2014 Filed Dec 1, 2014 22:10 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $28.40 $0.00
Disclosure

SEC source: 0001209191-14-071977 · doc4.xml · derivative · entry 3

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2018-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully vested.

Read SEC document
November 28, 2014 Filed Dec 1, 2014 22:10 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 10,000 $120.03 $1,200,300.00
Disclosure

SEC source: 0001209191-14-071977 · doc4.xml · nonDerivative · entry 2

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,210

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1.

F2 · price: Open market sales reported on this line occurred at a weighted average price of $120.03 (range $120.00 to $120.15).

F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Read SEC document
November 28, 2014 Filed Dec 1, 2014 22:10 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionCommon Stock 10,000 $28.40 $284,000.00
Disclosure

SEC source: 0001209191-14-071977 · doc4.xml · nonDerivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,210

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 06, 2014 Filed Nov 7, 2014 21:25 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionStock Option (right to buy) · Derivative 9,900 $0.00 Strike: $29.84 $0.00
Disclosure

SEC source: 0001209191-14-067323 · doc4.xml · derivative · entry 3

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,900 shares

Expires 2017-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully vested.

Read SEC document
November 06, 2014 Filed Nov 7, 2014 21:25 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 9,900 $115.21 $1,140,579.00
Disclosure

SEC source: 0001209191-14-067323 · doc4.xml · nonDerivative · entry 2

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,210

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1.

F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $115.21 (range $115.00 to $115.59).

Read SEC document
November 06, 2014 Filed Nov 7, 2014 21:25 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionCommon Stock 9,900 $29.84 $295,416.00
Disclosure

SEC source: 0001209191-14-067323 · doc4.xml · nonDerivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,110

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 05, 2014 Filed Nov 5, 2014 22:24 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionStock Option (right to buy) · Derivative 100 $0.00 Strike: $29.84 $0.00
Disclosure

SEC source: 0001209191-14-066728 · doc4.xml · derivative · entry 13

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,900

Underlying: Common Stock · 100 shares

Expires 2017-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: Fully vested.

Read SEC document
November 05, 2014 Filed Nov 5, 2014 22:24 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 100 $111.86 $11,186.00
Disclosure

SEC source: 0001209191-14-066728 · doc4.xml · nonDerivative · entry 10

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,210

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1.

Read SEC document
November 05, 2014 Filed Nov 5, 2014 22:24 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionCommon Stock 100 $29.84 $2,984.00
Disclosure

SEC source: 0001209191-14-066728 · doc4.xml · nonDerivative · entry 9

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,310

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 04, 2014 Filed Nov 5, 2014 22:24 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $29.84 $0.00
Disclosure

SEC source: 0001209191-14-066728 · doc4.xml · derivative · entry 12

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2017-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: Fully vested.

Read SEC document
November 04, 2014 Filed Nov 5, 2014 22:24 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 100 $115.45 $11,545.00
Disclosure

SEC source: 0001209191-14-066728 · doc4.xml · nonDerivative · entry 8

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,210

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1.

Read SEC document
November 04, 2014 Filed Nov 5, 2014 22:24 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 4,400 $114.23 $502,612.00
Disclosure

SEC source: 0001209191-14-066728 · doc4.xml · nonDerivative · entry 7

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,310

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1.

F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F7 · price: Open market sales reported on this line occurred at a weighted average price of $114.23 (range $113.95 to $114.71).

Read SEC document
November 04, 2014 Filed Nov 5, 2014 22:24 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 3,200 $113.47 $363,104.00
Disclosure

SEC source: 0001209191-14-066728 · doc4.xml · nonDerivative · entry 6

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,710

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1.

F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F6 · price: Open market sales reported on this line occurred at a weighted average price of $113.47 (range $112.91 to $113.88).

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.